<DOC>
	<DOCNO>NCT00003346</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy consist acetaminophen plus carmustine treating patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) optimal biologic dose ( OBD ) high-dose acetaminophen give alone , MTD carmustine give acetaminophen OBD patient metastatic melanoma ( Phase I close accrual 3/7/2001 ) . - Determine dose acetaminophen result maximal depletion intracellular glutathione patient . - Assess antitumor activity high-dose acetaminophen patient . - Assess toxicity antitumor activity carmustine administer high-dose acetaminophen patient . OUTLINE : This dose-escalation study . - Phase I : ( close accrual 3/7/2001 ) Patients receive single oral dose acetaminophen , acetylcysteine IV 20 hour , begin 6-8 hour acetaminophen . This treatment repeat 3 week later . On day 1 first treatment , patient also receive carmustine IV 1 hour , acetylcysteine . Courses repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos acetaminophen determine optimal biological dose ( OBD ) . The OBD define low dose precede maximum tolerate dose ( MTD ) result maximal depletion glutathione . The MTD define dose 1 6 patient experience dose-limiting toxicity ( DLT ) . Once OBD establish acetaminophen , cohort 3-6 patient receive escalate dos carmustine . The MTD define acetaminophen . Dose escalation proceed patient observe 6 week receive carmustine . Once OBD acetaminophen MTD carmustine determine , 3 patient treat 3 week interval instead 6 week . If DLT observe , dose schedule phase II portion study . - Phase II : A cohort 14 patient receive oral acetaminophen acetylcysteine IV every 3 week . Another cohort 14 patient receive oral acetaminophen acetylcysteine IV , oral acetaminophen , carmustine IV , acetylcysteine IV 3 week later . Patients continue therapy absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 30-80 patient accrue study within 40 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV melanoma stage III melanoma potentially curable surgery Phase I : ( close accrual 3/7/2001 ) measurable evaluable disease require Phase II : At least 2 measurable subcutaneous cutaneous metastasis accessible biopsy PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm^3 No active bleeding Hepatic : AST le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase less 1.5 time ULN PT/PTT within normal range Renal : Not specify Pulmonary : No interstitial lung disease unexplained interstitial infiltrates chest xray No chronic obstructive pulmonary disease No asthma require treatment Other : No active infection require antimicrobial drug Not pregnant nursing Fertile patient must use effective barrier contraception No allergy acetaminophen acetylcysteine PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week mitomycin ) No prior nitrosoureas No prior hepatic perfusion chemotherapy Endocrine therapy : No concurrent oral contraceptive Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent vitamin , mineral , garlic supplement At least 7 day since prior garlic alcohol No concurrent treatment medication know affect P450 hepatic enzymes No concurrent treatment calcium channel blocker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>